Mortality before hospital discharge · preterm infants at risk of respiratory distress syndrome
It is very uncertain whether surfactant treatment guided by rapid tests for surfactant deficiency changes mortality prior to hospital discharge№ of participants: 562 (3 RCTs) compared with surfactant therapy provided to preterm infants with respiratory… (very low certainty).
1 finding from 1 review
RR 1.25 [0.65, 2.41]
Studies not reported
Very low
Bronchopulmonary dysplasia · preterm infants at risk of respiratory distress syndrome
Surfactant treatment guided by rapid tests for surfactant deficiency showed no clear difference in bronchopulmonary dysplasia№ of participants: 562(3 RCTs) compared with surfactant therapy provided to preterm infants with respiratory… (low certainty).
1 finding from 1 review
RR 0.9 [0.61, 1.32]
Studies not reported
Low
Bronchopulmonary dysplasia or mortality ‐ not reported · preterm infants at risk of respiratory distress syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Surfactant utilization № of participants: 562 (3 RCTs) · preterm infants at risk of respiratory distress syndrome
Surfactant treatment guided by rapid tests for surfactant deficiency showed no clear difference in surfactant utilization № of participants: 562 (3 RCTs) compared with surfactant therapy provided to preterm infants with respiratory… (low certainty).
1 finding from 1 review
RR 0.97 [0.85, 1.11]
Studies not reported
Low
Pneumothorax · preterm infants at risk of respiratory distress syndrome
Surfactant treatment guided by rapid tests for surfactant deficiency showed no clear difference in any pneumothorax№ of participants: 506(2 RCTs) compared with surfactant therapy provided to preterm infants with respiratory… (low certainty).
1 finding from 1 review
RR 0.53 [0.15, 1.92]
Studies not reported
Low
Neurodevelopmental outcomes · preterm infants at risk of respiratory distress syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adherence to strategies: uptake of rapid antigen test (over 13‐week · school staff
1 finding from 1 review
Rapid sodium increase · chronic non‐hypovolaemic hypotonic hyponatraemia
Vasopressin receptor antagonists probably leads to higher rapid sodium increase compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality sensitivity analysis (calculated instead of overall survival) ‐ without UK NCRI Rapid trial and MSKCC trial #90‐44due to high risk of other bias
The intervention probably leads to lower mortality sensitivity analysis (calculated instead of overall… (moderate certainty).
1 finding from 1 review
Short‐term (within 1 month) change in isolated movement, objective and subjective measures of speech production Wessel 1995: Mean syllable duration during rapid‐syllable repetition task. Scale from: 1 to 500. Shorter durations are better. · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
no estimate extracted
4 participants
Very low
Tranquillisation or asleep · psychosis‐induced aggression or agitation (rapid tranquillisation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global state: non‐responders to the first injection · psychosis‐induced aggression or agitation (rapid tranquillisation)
ARIPIPRAZOLE (IM) showed no clear difference in global state: non‐responders to the first injection compared with OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (low certainty).
1 finding from 1 review
Adverse effects: one or more adverse events during 24 hours (only reported if occurred in ≥ 5% of people) · psychosis‐induced aggression or agitation (rapid tranquillisation)
It is very uncertain whether ARIPIPRAZOLE (IM) changes adverse effects: one or more adverse events during 24 hours (only… compared with OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (very low certainty).
1 finding from 1 review
Adverse effects: movement disorders ‐ EPS during 24 hours (only reported if occurred in ≥ 5% of people) · psychosis‐induced aggression or agitation (rapid tranquillisation)
It is very uncertain whether ARIPIPRAZOLE (IM) changes adverse effects: movement disorders ‐ EPS during 24 hours (only… compared with OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (very low certainty).
1 finding from 1 review
Economic outcomes · psychosis‐induced aggression or agitation (rapid tranquillisation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tranquillisation or asleep · psychosis‐induced aggression or agitation (rapid tranquillisation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Repeated need for tranquillisation ‐ not reported · psychosis‐induced aggression or agitation (rapid tranquillisation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Specific behaviour: Agitation ‐ clinically important change (PANSS ‐EC reduction ≥ 40% from baseline) ‐ up to 2 hours · psychosis‐induced aggression or agitation (rapid tranquillisation)
ARIPIPRAZOLE (IM) may leads to lower specific behaviour: Agitation ‐ clinically important change (PANSS… compared with OTHER ANTIPSYCHOTIC: b. OLANZAPINE (low certainty).
1 finding from 1 review
Global state: CGI‐S change score up to 2 hours · psychosis‐induced aggression or agitation (rapid tranquillisation)
1 finding from 1 review
Adverse effects: one or more adverse effects during 24 hours · psychosis‐induced aggression or agitation (rapid tranquillisation)
It is very uncertain whether ARIPIPRAZOLE (IM) changes adverse effects: one or more adverse effects during 24 hours compared with OTHER ANTIPSYCHOTIC: b. OLANZAPINE (very low certainty).
1 finding from 1 review